A New Pfizer Inc. Bid For AstraZeneca plc?

A fresh takeover attempt at AstraZeneca plc (LON: AZN) could happen as early as later this week.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazeneca2AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares have climbed 8% over the past week to 4,442p, fuelled by speculation that a fresh takeover bid from Pfizer in the US could soon be launched.

Pfizer’s earlier bid was finally withdrawn in late May after the AstraZeneca board gave the idea the coldest of shoulders.

But Pfizer was keen to get its hands on London’s second-biggest pharmaceuticals firm for two reasons.

Drugs and taxes

Firstly, Pfizer needs to seriously boost its pipeline, and even after such a short time in its refocus plan, AstraZeneca is already seeing results. At the first-half stage this year, there were 14 projects in Phase III, up from 8 a year previously, moving chief executive Pascal Soriot to say “we now have one of the most exciting pipelines in the industry“. That number is now up to 15.

Pfizer also wants to minimize taxes, and one way would be to acquire a company like AstraZeneca and shift its tax base to the UK.

Takeover regulations

UK takeover regulations usually mandate a minimum six-month waiting period before a fresh approach can be made — taking us to 26 November. But there are exceptions, and a takeover target can invite the bidder back after three months. That would seem unlikely, but there is one further option — a bidder can make a single bid if it is confident the target will accept it for recommendation to shareholders.

Few are actually expecting anything as early as this week — most are suggesting any new approach would not happen until November or December.

It’s far from certain there will be a new bid anyway, after Pfizer wouldn’t raise its £55 offer in May — that valued AstraZeneca at £70bn, taking it ahead of rival GlaxoSmithKline. At the time, the AstraZeneca board said they’d only look at offers of at least £58.85.

astrazenecaReceding target?

Some investors were miffed at not making a quick profit last time. But a key member of the opposition was Neil Woodford, who reckoned shareholders would do better in the long term by telling Pfizer where to stick its offer.

And we’ll be looking at the results of six more months of pipeline development at AstraZeneca, which will surely only increase the price at which a takeover is likely to succeed — pushing it even further than Pfizer might be willing to pay right now.

Sights elsewhere?

Pfizer might also seek an overseas tax base elsewhere, and come commentators are already suggesting other takeover targets.

Whatever happens, the next few months could be a tense time for AstraZeneca shareholders.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »